Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar

Boehringer Ingelheim, which recently launched the first interchangeable biosimilar to AbbVie’s megablockbuster Humira, is getting in on the industry’s double-pricing trick.

After debuting its branded Humira biosim Cyltezo in July, Boehringer has launched an unbranded copycat of the inflammatory disease drug, simply called adalimumab-adbm injection, which will be sold at an 81% discount to Humira. By comparison, BI's Cyltezo carries a 5% discount to the branded med.